Hyppää sisältöön
    • Suomeksi
    • In English
  • Suomeksi
  • In English
  • Kirjaudu
Näytä aineisto 
  •   Etusivu
  • 3. UTUCris-artikkelit
  • Rinnakkaistallenteet
  • Näytä aineisto
  •   Etusivu
  • 3. UTUCris-artikkelit
  • Rinnakkaistallenteet
  • Näytä aineisto
JavaScript is disabled for your browser. Some features of this site may not work without it.

Macrophage-Targeted Lung Delivery of Dexamethasone Improves Pulmonary Fibrosis Therapy via Regulating the Immune Microenvironment

Yang Jian; Tian Fei; Qi Dawei; Wang Yuanyuan; Zhu Yan; Xue Zhifeng; Sang Xiaoqing; Fan Gunwei

Macrophage-Targeted Lung Delivery of Dexamethasone Improves Pulmonary Fibrosis Therapy via Regulating the Immune Microenvironment

Yang Jian
Tian Fei
Qi Dawei
Wang Yuanyuan
Zhu Yan
Xue Zhifeng
Sang Xiaoqing
Fan Gunwei
Katso/Avaa
Publisher's version (4.651Mb)
Lataukset: 

doi:10.3389/fimmu.2021.613907
Näytä kaikki kuvailutiedot
Julkaisun pysyvä osoite on:
https://urn.fi/URN:NBN:fi-fe2021042826841
Tiivistelmä
Idiopathic pulmonary fibrosis (IPF) is serious chronic lung disease with limited therapeutic approaches. Inflammation and immune disorders are considered as the main factors in the initiation and development of pulmonary fibrosis. Inspired by the key roles of macrophages during the processes of inflammation and immune disorders, here, we report a new method for direct drug delivery into the in-situ fibrotic tissue sites in vitro and in vivo. First, liposomes containing dexamethasone (Dex-L) are prepared and designed to entry into the macrophages in the early hours, forming the macrophages loaded Dex-L delivery system (Dex-L-MV). Chemokine and cytokine factors such as IL-6, IL-10, Arg-1 are measured to show the effect of Dex-L to the various subtypes of macrophages. Next, we mimic the inflammatory and anti-inflammatory microenvironment by co-culture of polarized/inactive macrophage and fibroblast cells to show the acute inflammation response of Dex-L-MV. Further, we confirm the targeted delivery of Dex-L-MV into the inflammatory sites in vivo, and surprisingly found that injected macrophage containing Dex can reduce the level of macrophage infiltration and expression of the markers of collagen deposition during the fibrotic stage, while causing little systematic toxicity. These data demonstrated the suitability and immune regulation effect of Dex-L-MV for the anti-pulmonary process. It is envisaged that these findings are a step forward toward endogenous immune targeting systems as a tool for clinical drug delivery.
Kokoelmat
  • Rinnakkaistallenteet [19176]

Turun yliopiston kirjasto | Turun yliopisto
julkaisut@utu.fi | Tietosuoja | Saavutettavuusseloste
 

 

Tämä kokoelma

JulkaisuajatTekijätNimekkeetAsiasanatTiedekuntaLaitosOppiaineYhteisöt ja kokoelmat

Omat tiedot

Kirjaudu sisäänRekisteröidy

Turun yliopiston kirjasto | Turun yliopisto
julkaisut@utu.fi | Tietosuoja | Saavutettavuusseloste